WHO's New Essential Medicines List Includes Crucial Treatments for People with Albinism

In a significant development for the albinism community worldwide, the World Health Organization (WHO) has updated its Essential Medicines List to include sunscreen as a vital treatment for people with albinism.

According to Human Rights Watch, this change represents a crucial advocacy victory that could improve access to necessary sun protection for millions of people with albinism globally, especially in regions where access to sunscreen has been limited by cost and availability.

The WHO's Essential Medicines List serves as a guide for countries when making decisions about which medications and treatments should be made available to their populations at affordable costs. The inclusion of sunscreen specifically for people with albinism recognizes the critical importance of sun protection in preventing skin cancer and other sun-related health complications that disproportionately affect this community.

Protection Against a Leading Cause of Mortality

Skin cancer remains one of the leading preventable causes of death among people with albinism in regions with high sun exposure. Without melanin's natural protection, individuals with albinism face significantly higher risks of developing aggressive skin cancers, often at young ages.

The WHO guidance acknowledges this reality by categorizing sunscreen as an essential medication rather than a cosmetic product — a distinction that could help reduce import taxes, lower costs, and improve distribution in countries where people with albinism have historically struggled to access adequate sun protection.

Broader Health Advocacy Wins

The updated list also includes expanded treatments for diabetes, demonstrating WHO's commitment to addressing non-communicable diseases that affect millions worldwide.

For the albinism community, this development comes after years of advocacy by organizations and individuals who have emphasized that sunscreen is not a luxury but a life-saving necessity for people with albinism.

This policy change has the potential to influence national health systems, particularly in Africa and other regions where albinism is prevalent but healthcare resources are limited. By following WHO guidance, countries may now be more likely to subsidize or provide sunscreen through public health programs.

As implementation begins, advocates will be watching closely to see how quickly this policy translates into improved access to sunscreen for people with albinism in communities where it's most needed.